We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Daniel
Freeman
daniel.freeman@psy.ox.ac.uk
Dr
Eloise
Prouten
eloise.prouten@psy.ox.ac.uk
Dr
Julia
Jones
julia.jones@psy.ox.ac.uk
Agoraphobic avoidance (severe) in patients with a diagnosis of psychosis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study aims to evaluate gameChange, a virtual reality (VR) treatment for people with psychosis, in real-world settings within the NHS. The goal is to help the National Institute for Health and Care Excellence (NICE) decide whether to fully recommend gameChange for use in the NHS. The project is funded by the National Institute for Health and Social Care Research (NIHR) and supported by the Office for Life Sciences (OLS) and NICE.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2025 Protocol article in https://pubmed.ncbi.nlm.nih.gov/40819857/ (added 18/08/2025)
You can take part if:
You may not be able to take part if:
1. Photosensitive epilepsy. 2. In forensic settings or Psychiatric Intensive Care Unit.3. Command of spoken English inadequate for engaging in the therapy or assessments.4. A participant may also not enter the trial if there is another factor (for example, current active suicidal plans that need to be the focus of intervention), which, in the judgement of the investigator, would preclude the participant from providing informed consent or from safely engaging with the trial procedures. Reason for exclusion will be recorded.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Daniel
Freeman
daniel.freeman@psy.ox.ac.uk
Dr
Julia
Jones
julia.jones@psy.ox.ac.uk
Dr
Eloise
Prouten
eloise.prouten@psy.ox.ac.uk
The study is sponsored by University of Oxford and funded by National Institute for Health and Care Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS: 67294
You can print or share the study information with your GP/healthcare provider or contact the research team directly.